Merck & Co., Inc. (MRK) - Comprehensive Stock Analysis Report
📋 Investment SnapshotIs MRK a buy right now? The 10-second read
Reason: Tradable setup, mediocre business. Expected Return is the upside to the analyst price target; full rationale is detailed below.
📌 Is MRK a Buy right now?
According to Ultra Stock Analysis Pro, Merck & Co., Inc. (MRK) is currently rated HOLD (Signal Strength: 0/7 (no confluence event in the last 30 days)). The long-term fundamentals are stable (P/E: 108.7, Revenue Growth: +5.1%), while short-term technicals show a bullish trend (RSI: 69). Consider waiting for support confirmation near $135.55 before adding exposure.
Key takeaways
- Rating & timing: rated HOLD (Signal Strength 0/7), model timing GREEN · BULLISH, WATCHING FOR ENTRY · EXTENDED.
- Stop loss: the Conservative fixed 2.0x ATR stop sits at $129.25, 4.9% below the current $135.84.
- Growth vs. valuation: revenue +5.1% YoY with a -0.2% operating margin, at a forward P/E of 14.2x.
- Wall Street: average target $137.73 (+1.4%) from 19 Buy, 10 Hold, 0 Sell ratings.
- Key levels: nearest support $135.05 (-0.6%), nearest resistance $135.55 (-0.2%).
For the latest stock analysis and interactive charts:
📊 Open MRK Analysis ↗
⚡ QUICK DECISIONShould you buy, hold or wait on MRK stock today?
💡 Why This Signal ExistsWhy does MRK carry this rating?
MRK carries a WAIT rating because relative strength is positive versus the S&P 500, but fundamentals are weak (Investment Quality 34/100), trend strength is still emerging (ADX 21) and no fresh entry trigger has fired (Signal Strength 0/7). A breakout above $139.24 on improving volume would upgrade the signal toward BUY; a break below $135.05 would mark deeper weakness.
🎯 CONSENSUS HUDWhat is the Wall Street analyst consensus on MRK?
The call itself, and the readings behind it. Details read supportive / caution / headwind.
Action plan
MAINTAIN POSITION — currently +14.3% unrealized. Manage it with the stop levels below.
🎯 Intelligent Stop Loss Strategy
Current Price
$135.84
Buy Stop Loss
$129.25
Distance: 5%
Conservative 2.0x
Position Stop Loss
$130.90
Distance: 4%
Hybrid 1.50x
ATR 14 Day
$3.30
Volatility
ADX Strength
21.3
Emerging trend
Position up +14% - Adaptive strategy adjusts for momentum
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
🔮 FUTURE PRICE SCENARIOS (AI Forecast)Where could MRK stock go over the next week?
To assist with risk management, here are the three most probable paths for MRK over the next trading week:
🟢 The Bull Case (Probability: 20%)
If MRK reclaims the $135.55 resistance level, algorithmic targets shift to $137.73. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $135.05 support level triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $121.09 liquidity zone (-10.9% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 21 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $135.05 and $135.55 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
⚠️ RISK HUD — DEEP DIVEWhat are the biggest risks of buying MRK now?
Five risk axes scored LOW / MODERATE / HIGH, then the mitigation that follows from them.
📊 BUY-SIDE HUDHow much MRK should you own, and can you trade it at size?
Portfolio-management read: how much to own, what the historical edge is, and whether the position can be traded at size. Details below read supportive / caution / headwind; grey is context, not a verdict.
📈 SELL-SIDE HUDIs MRK stock overvalued or undervalued?
Research read: Merck & Co., Inc. · Healthcare · Drug Manufacturers - General. What the business is worth and where the Street stands. Details below read supportive / caution / headwind; grey is context, not a verdict.
🧭 Investment Quality vs. Entry QualityHow does MRK's investment quality compare to its entry quality?
Two independent reads: how good the business is (fundamentals) vs. how stretched the price is against its recent range. Entry Quality is a mean-reversion score — it marks a stock down for trading near the top of its range. It is not the model's timing call, which is GREEN · BULLISH, WATCHING FOR ENTRY · EXTENDED and appears in the Consensus HUD above.
Weak on both fronts. Neither MRK's business nor its current timing stands out.
🧮 Factor AttributionWhat is actually driving MRK's rating?
What is driving the view — every factor's signed contribution to one net score. Green adds to the bull case; red detracts.
| Factor | Contribution | Pts |
|---|---|---|
| Valuation Fwd P/E 14.2, PEG 2.8 | +15 | |
| Trend EMA bullish, ADX 21 | +8 | |
| Relative Strength +7.5% vs benchmarks (3M) | +8 | |
| Momentum RSI 69, MACD bullish | +5 | |
| Revenue Growth +5% YoY | +3 | |
| Sentiment Slightly Bullish | +2 | |
| Earnings Growth +0% YoY | +0 | |
| Volatility ATR 2.4% of price | -1 | |
| Profitability Margin 5%, ROE 7% | -4 |
Net Factor Score: +36 — Net bullish. This weighs the broad bull/bear case; the entry signal (Signal Strength) governs timing — a strong factor score can still read WAIT until a setup triggers.
🏆 Relative StrengthIs MRK outperforming the S&P 500 and its sector?
The stock's return minus each benchmark's return. Positive = outperforming = leadership; negative = lagging. Relative strength is one of the most durable signals in quantitative research.
| Benchmark | 1-Mo | 3-Mo | 6-Mo |
|---|---|---|---|
| S&P 500 (SPY) | +3.0% | +16.6% | +1.0% |
| Healthcare (XLV) | +3.0% | +6.0% | +7.4% |
| Pharma (XPH) | +1.0% | -0.1% | -9.6% |
MRK 3-month return: +20.6% · Leadership: MARKET LEADER — outperforming the S&P 500
🤖 ML ProbabilityWhat is the probability MRK stock closes higher?
A gradient-boosted model's estimated probability that price closes higher over each horizon (directional estimate, not a guarantee).
📊 Valuation & Fundamentals vs Drug Manufacturers - General (11 peers)Is MRK cheap or expensive versus its sector peers?
● Top 25% in sector ● Middle 50% ● Bottom 25% — each value colored by its rank among 11 Drug Manufacturers - General peers; "med" is the peer median.
⚔️ MRK vs. Its Closest PeersHow does MRK compare to PFE and its other closest peers?
The closest business match first, then the nearest by market cap within Drug Manufacturers - General from the live sector screener. Industry classification alone is not enough — it files MRK beside companies in a different line of business — so the direct competitor is seeded explicitly. Green marks the best reading in each row, red the worst.
| Metric | MRK (this report) | PFE | ABBV | AMGN |
|---|---|---|---|---|
| Market Cap | $335.1B | $152.7B | $440.8B | $224.1B |
| Revenue Growth (YoY) | +5.1% | +2.6% | +10.2% | +9.5% |
| Forward P/E | 14.2x | 9.3x | 15.3x | 17.1x |
| PEG Ratio | 2.79 | 2.55 | 0.41 | 2.18 |
| Operating Margin | -0.2% | 27.9% | 40.0% | 35.5% |
| Trend Strength (ADX) | 21.3 | 25.7 | 21.6 | 32.1 |
PFE (Pfizer Inc. — closest business match), ABBV (AbbVie Inc.), AMGN (Amgen Inc.). Peers marked “closest business match” come from the curated rival map; the rest are the nearest by market cap in the same industry. ADX is shown where recent price data is already on file for that peer.
🎯 ANALYST PRICE TARGETSHow high could MRK go? The full target range
| Average Target: | $137.73 | High Target: | $155.00 |
| Current Price: | $135.84 | Low Target: | $105.00 |
| Upside to Average: | +1.4% | Number of Analysts: | 26 |
🔔 ANALYST RATING CHANGESHave analysts upgraded or downgraded MRK recently?
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| Daiwa Capital | UPGRADE | Neutral → Outperform | Aug 12, 2026 |
| RBC Capital | REITERATED | Outperform → Outperform | Jul 08, 2026 |
| Cantor Fitzgerald | REITERATED | Neutral → Neutral | Jul 06, 2026 |
| CICC | INITIATED | Outperform | Jun 24, 2026 |
News Sentiment (14-Day)What is the latest news sentiment on MRK?
Overall Score: 2.3/10 - Slightly Bullish
Bullish Articles (Top 5 of 2)
- Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress
Simply Wall St. • Aug 13Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. ...
Source: https://finance.yahoo.com/markets/stocks/articles/merck-mrk-... - 5 Insightful Analyst Questions From Merck’s Q2 Earnings Call
StockStory • Aug 12Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new pro...
Source: https://finance.yahoo.com/healthcare/articles/5-insightful-a...
📊 Sentiment Interpretation
The news sentiment is moderately bullish, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.
📊 Strategy Comparison: Conservative vs Adaptive
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Adaptive adjusts stops based on position profit (tighter as profit grows).
Conservative Strategy
OPEN POSITIONFixed 2.0x ATR Stop Loss
Entry: $118.87 on 2026-05-26
Confluence: 4/7 (4d before entry)
Stop Loss: $129.25
Backtest Results (Since 2018):
Past Win Rate
50%
Past Total Return
+19.9%
Max Drawdown
-11.7%
Avg Trade
+2.2%
Trades
20
Adaptive Strategy
OPEN POSITIONAdaptive ATR Stop Loss (1.0-2.75x)
Entry: $118.87 on 2026-05-26
Confluence: 4/7 (4d before entry)
Stop Loss: $130.90
Backtest Results (Since 2018):
Past Win Rate
52%
Past Total Return
+23.8%
Max Drawdown
-8.6%
Avg Trade
+2.4%
Trades
21
EXECUTIVE SUMMARY - Essential MetricsWhat are the key metrics for MRK stock?
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $135.84 | Market Cap | $335.1B |
| Past Win Rate (Backtest) | 50.0% (20 trades) | Forward P/E | 14.2x |
| Past Total Return | +19.9% | Analyst Target | $137.73 |
| RSI / Trend Strength | 69 / 21 | Upside to Target | +1.4% |
| MACD Signal | Bullish | Revenue Growth | +5.1% |
| Profit Factor | 1.77 | Institutional Own. | 82.8% |
| Position Entry | 2026-05-26 @ $118.87 | Analyst Ratings | 19 Buy / 10 Hold / 0 Sell |
| Open Position Past P&L | +14.3% |
🤖 ALGORITHMIC CONVICTION & METHODOLOGYHow is the MRK rating calculated?
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to MRK based on a confluence of 3 distinct factors:
- Technical Momentum: The RSI (69) is currently showing strong momentum in 50% of 20 backtested trades.
- Trend Strength: ADX at 21 indicates an emerging trend (20-25). News sentiment is neutral (Slightly Bullish).
- Volatility Profile: The ATR ($3.30) indicates moderate volatility (2.4% of price), suggesting potential moves of 4.9%+ on breakouts.
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 50% of the time across 20 historical trades over a medium-term (months) hold period, with an average return of +2.2% per trade.
📊 How the Signal Strength score works (and why it can read low in an uptrend)
Signal Strength is a tactical entry-timing score, not a trend or fundamentals grade. It only adds points from setups that flag a fresh reason to enter — breakouts, momentum divergences, and oversold/volume/volatility extremes. Trend direction and fundamentals are scored in their own sections above. A setup must reach 3+ points to register as a signal and 5+ for a strong BUY. Individual boxes below can be checked — a stacked EMA trend alone is worth 2 points — without crossing the 3-point bar; when that happens the registered Signal Strength stays at 0/7, meaning no new entry trigger today — not a bearish call.
| Signal | Pts | What it flags | Now |
|---|---|---|---|
| Valid Breakout | 3 | Close breaks above the 20-day high on >1.5× volume | ✗ |
| EMA Trend Alignment | 2 | EMA20 > EMA50 > EMA200 (stacked uptrend) | ✓ |
| RSI Bullish Divergence | 2 | Price firms while RSI was falling — a reversal setup | — |
| MACD Bullish Divergence | 2 | Price firms while MACD was falling — a reversal setup | — |
| Strong Trend (ADX > 25) | 1 | ADX > 25 confirming the stacked EMAs | ✗ |
| High Volume (>1.5×) | 1 | Volume surge confirming the move | ✗ |
| RSI Oversold | 1 | RSI < 30 — stretched to the downside (bounce setup) | ✗ |
| Below Lower Bollinger | 1 | Close below the lower band (mean-reversion setup) | ✗ |
| Volume Accumulation | 1 | Up-volume divergence — quiet accumulation | — |
This is why MRK can show a bullish EMA trend and solid fundamentals while Signal Strength reads 0/7: those are already-in-trend and value measures, whereas this score fires only on a new tactical setup (an oversold bounce, a divergence, or a high-volume breakout) — none of which is present on the latest bar.
❓ MRK — Common Questions
Every answer below is generated from the same figures as the report above, as of the data date on the cover.
📊 APPENDIX A - Complete Technical Indicators
Comprehensive technical data for quantitative analysis, grouped by what each indicator measures. Price leads; the three Bollinger bands sit together with the band position that reads them.
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Price & Volume | |||
| Current Price | $135.84 | Volume | 6.9M |
| Avg Volume | 10.2M | Beta | 0.21 |
| Trend | |||
| EMA 20 | $130.05 | EMA 50 | $126.02 |
| EMA 200 | $113.52 | VWAP | $135.07 |
| Trend Strength (ADX) | 21.28 | Distance from EMA 20 | +4.5% |
| Momentum | |||
| RSI (14) | 68.81 | MACD | 2.30 |
| MACD Signal | 1.89 | MACD Histogram | 0.41 |
| Stochastic %K | 91.06 | Stochastic %D | 74.66 |
| Bollinger Bands (20, 2σ) | |||
| Bollinger Upper | $135.55 | Bollinger Middle | $129.97 |
| Bollinger Lower | $124.38 | Band Position | 102.6% (0% = lower band, 100% = upper) |
| Volatility | |||
| ATR (14) | $3.30 | ATR as % of price | 2.4% |
| Signal | |||
| Confluence Score | 0/7 (no confluence event in the last 30 days) | Trade Signal | None in the last 30 days |
💼 APPENDIX B - Complete Fundamental Metrics
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $335.1B | Revenue | $66.6B |
| Forward P/E | 14.2 | Revenue Growth | +5.1% |
| Trailing P/E | 108.7 | Gross Margin | 75.9% |
| Price/Sales | 5.03 | Operating Margin | -0.2% |
| Price/Book | 7.31 | Profit Margin | 4.8% |
| PEG Ratio | 2.79 | ROE | 7.0% |
| Enterprise Value | $382.0B | Free Cash Flow | $15.2B |
| EPS (Forward) | $9.56 | Dividend Yield | 2.50% |
| 52-Week Range | $77.58 - $135.97 | ||
📈 APPENDIX C - Complete Trade History & Backtest Results
Comprehensive Trading Performance and Position Details
Backtest Performance Metrics
Current Open Position
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-05-26 | $118.87 | +14.28% | $114.98 |
Recent Trade History (Last 10 Trades)
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2022-11-30 | 2022-12-14 | $98.40 | $100.33 | +1.97% | Win |
| 2023-01-27 | 2023-06-07 | $94.78 | $98.37 | +3.78% | Win |
| 2023-10-19 | 2024-02-07 | $92.19 | $117.86 | +27.84% | Win |
| 2024-03-27 | 2024-04-11 | $122.59 | $117.38 | -4.25% | Loss |
| 2024-06-28 | 2024-07-16 | $115.88 | $117.42 | +1.32% | Win |
| 2024-11-15 | 2025-02-07 | $90.75 | $82.90 | -8.65% | Loss |
| 2025-04-16 | 2025-07-25 | $73.25 | $81.97 | +11.90% | Win |
| 2025-10-02 | 2025-10-17 | $87.47 | $82.86 | -5.27% | Loss |
| 2025-11-18 | 2026-01-08 | $94.23 | $109.39 | +16.08% | Win |
| 2026-02-03 | 2026-04-28 | $114.17 | $109.24 | -4.31% | Loss |
Summary: 20 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Run a Live Real-Time Scan of MRK
This report is a snapshot through 2026-08-14. Get current technicals, fresh AI news sentiment, and up-to-the-minute stop-loss levels for MRK — free, no signup.
▶ Run Live MRK Analysis →